2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals

M. Rondy, O. Launay, J. Puig-Barberà, G. Gefenaite, J. Castilla, K. de Gaetano Donati, F. Galtier, E. Hak, M. Guevara, S. Costanzo, A. Moren, Nezha Lenzi, Zineb Lesieur, Isabelle Bonmarin, Xavier Duval, Yolande Costa, Annuxcy Kanagaratnam, Yazdan Yazdapanah, Marion Caseris, Nathalie DournonThomas Papo, Antoine Dossier, Hakim Bécheur, Anne Laure Pelletier, Hervé Mal, Armelle Marceau, Michel Aubier, Raphaêl Bories, Enrique Casalino, Christophe Choquet, Nadhira Houhou, Pierre Loulergue, Reem Kanaan, Florence Dumas, Déborah Postil, Sébastien Alcoléa, Sylvie Rogez, Philippe Vanhaems, Corinne Régis, Corinne Merle, Vincent Foulongne, Marine Ray, Véronique Maugueret-Doublet, Arnaud Bourdin, Liliane Landreau, Amadou Konaté, Philippe Corne, Mustapha Sebbane, Kada Klouche, Marie Suzanne Léglise, Martine Valette, Bruno Lina, Fabrice Carrat, Frédéric Chau, Javier Díez-Domingo, Begoña Escribano-López, Alberto Arnedo-Pena, Montserrat Ruiz-García, Miguel Tortajada-Girbés, Consuelo Carratalá Munuera, Julio Barrenengoa Sañudo, Rosa Larrea-González, Vicente Gil-Guillén, German Schwarz-Chavarri, Janette Rahamat-Langendoen, Hubert Niesters, Arvydas Ambrozaitis, Ligita Jancoriene, Aukse Mickiene, Monika Kuliese, Daiva Velyvyte, Ronald P. Stolk, Kestutis Zagminas, Carmen Ezpeleta, Judith Chamorro, Pilar Artajo, Francisco Lameiro, Ana Navascués, Maite Ortega, Montse Torres, José Javier García Irure, Fátima Irisarri, Manuel García Cenoz, Iván Martínez-Baz, Roberto Cauda, Concetta Donato, Rosaria Santangelo, Francesco Perlasca, Giovanni Fichera, Marianna Dara, Licia Iacoviello, Marco Olivieri

Research output: Contribution to journalArticlepeer-review

Abstract

While influenza vaccines aim to decrease the incidence of severe influenza among high-risk groups, evidence of influenza vaccine effectiveness (IVE) among the influenza vaccine target population is sparse. We conducted a multicentre test-negative case–control study to estimate IVE against hospitalised laboratoryconfirmed influenza in the target population in 18 hospitals in France, Italy, Lithuania and the Navarre and Valencia regions in Spain. All hospitalised patients aged ≥18 years, belonging to the target population presenting with influenza-like illness symptom onset within seven days were swabbed. Patients positive by reverse transcription polymerase chain reaction for influenza virus were cases and those negative were controls. Using logistic regression, we calculated IVE for each influenza virus subtype and adjusted it for month of symptom onset, study site, age and chronic conditions. Of the 1,972 patients included, 116 were positive for influenza A(H1N1)pdm09, 58 for A(H3N2) and 232 for influenza B. Adjusted IVE was 21.3% (95% confidence interval (CI): -25.2 to 50.6; n=1,628), 61.8% (95% CI: 26.8 to 80.0; n=557) and 43.1% (95% CI: 21.2 to 58.9; n=1,526) against influenza A(H1N1) pdm09, A(H3N2) and B respectively. Our results suggest that the 2012/13 IVE was moderate against influenza A(H3N2) and B and low against influenza A(H1N1) pdm09.

Original languageEnglish
Article number21011
JournalEuro surveillance : bulletin européen sur les maladies transmissibles = European communicable disease bulletin
Volume20
Issue number2
Publication statusPublished - Jan 15 2015

ASJC Scopus subject areas

  • Epidemiology
  • Public Health, Environmental and Occupational Health
  • Virology

Fingerprint

Dive into the research topics of '2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals'. Together they form a unique fingerprint.

Cite this